Daiichi Sankyo Company Limited

Compare

21 Followers

4568 Stock Chart & Stats

¥3669.00

-¥99.00(-2.29%)

At close: Jan 08 4:00 PM EST

¥3669.00

-¥99.00(-2.29%)

Day’s Range― - ―

52-Week Range¥3,036.00 - ¥5,053.00

Previous CloseN/A

Volume4.34M

Average Volume (3M)6.53M

Market Cap

$7.65T

Enterprise Value¥5.88T

Total Cash (Recent Filing)$574.30B

Total Debt (Recent Filing)$201.24B

Price to Earnings (P/E)25.3

Beta0.77

Next Earnings

Jan 30, 2026

EPS Estimate

42.58

Last Dividend Ex-Date

Sep 29, 2025

Dividend Yield1.64%

Share Statistics

EPS (TTM)24.52

Shares Outstanding1,894,350,600

10 Day Avg. Volume6,968,810

30 Day Avg. Volume6,527,236

Financial Highlights & Ratios

PEG Ratio0.46

Price to Book (P/B)4.10

Price to Sales (P/S)3.53

P/FCF Ratio-106.67

Enterprise Value/Market Cap0.77

Enterprise Value/Revenue3.06

Enterprise Value/Gross Profit3.89

Enterprise Value/Ebitda15.25

Forecast

1Y Price Target

$5,760.82

Price Target Upside57.01% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Corporate ConfidenceA recent JPY200Bn-buyback was conducted in defiance of the weak stock price, indicating confidence in the company's corporate value.

Drug DevelopmentAdvancing to Enhertu’s filing for 1L HER2+ BC with strong DB09 interim data shows promising progress in drug development.

FDA ApprovalFDA has approved anticancer candidate Dato-DXd for breast cancer, which is considered a positive surprise by the market.

Bears Say

Disappointing Study DataDaiichi's shares have declined by about 1/3 since the company reported disappointing Ph2 data from the TROPION-Lung01 study.

Stock DeclineDaiichi's shares have declined by about 1/3 since the company reported disappointing data from a lung cancer study.

Daiichi Sankyo Company News

DSKYF Upcoming Earnings Report: What to Expect?

Daiichi Sankyo Company (DSKYF) is scheduled to report 2nd quarter earnings on 10/31/2025. Regarding Q2 estimates, Wall Street...

5d ago

Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...

6d ago

DSKYF

Daiichi Sankyo’s Promising Pediatric Cancer Study: A Potential Game-Changer

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The LIGHTBEAM-U01 Substudy 01C,...

6d ago

DSKYF

Daiichi Sankyo’s Promising Gastrointestinal Cancer Study: A Market Game-Changer?

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...

6d ago

DSKYF

Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Gastrointestinal Cancer Treatment

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...

6d ago

DSKYF

Daiichi Sankyo’s Promising Breast Cancer Study: A Financial Perspective

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...

6d ago

DSKYF

Daiichi Sankyo’s Promising Phase 2 Breast Cancer Study: A Potential Game-Changer

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The study titled An...

6d ago

DSKYF

Daiichi Sankyo’s Promising Study on Innovative Lung Cancer Treatments

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...

6d ago

DSKYF

Daiichi Sankyo’s Promising Phase 3 Trial: A Potential Game-Changer in Gastric Cancer Treatment

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo Company is...

6d ago

DSKYF

Daiichi Sankyo’s Quizartinib Trial: A New Hope for AML Treatment?

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo is conducting...

6d ago

DSKYF

4568 FAQ

What was Daiichi Sankyo Company Limited’s price range in the past 12 months?

Daiichi Sankyo Company Limited lowest stock price was ¥3036.00 and its highest was ¥5053.00 in the past 12 months.

What is Daiichi Sankyo Company Limited’s market cap?

Daiichi Sankyo Company Limited’s market cap is $7.65T.

When is Daiichi Sankyo Company Limited’s upcoming earnings report date?

Daiichi Sankyo Company Limited’s upcoming earnings report date is Jan 30, 2026 which is in 88 days.

How were Daiichi Sankyo Company Limited’s earnings last quarter?

Daiichi Sankyo Company Limited released its earnings results on Oct 31, 2025. The company reported ¥24.52 earnings per share for the quarter, missing the consensus estimate of ¥44.829 by -¥20.309.

Is Daiichi Sankyo Company Limited overvalued?

According to Wall Street analysts Daiichi Sankyo Company Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Daiichi Sankyo Company Limited pay dividends?

Daiichi Sankyo Company Limited pays a Semiannually dividend of ¥39 which represents an annual dividend yield of 1.64%. See more information on Daiichi Sankyo Company Limited dividends here

What is Daiichi Sankyo Company Limited’s EPS estimate?

Daiichi Sankyo Company Limited’s EPS estimate is 42.58.

How many shares outstanding does Daiichi Sankyo Company Limited have?

Daiichi Sankyo Company Limited has 1,894,350,600 shares outstanding.

What happened to Daiichi Sankyo Company Limited’s price movement after its last earnings report?

Daiichi Sankyo Company Limited reported an EPS of ¥24.52 in its last earnings report, missing expectations of ¥44.829. Following the earnings report the stock price went down -4.503%.

Which hedge fund is a major shareholder of Daiichi Sankyo Company Limited?

Currently, no hedge funds are holding shares in JP:4568

Company Description

Daiichi Sankyo Company Limited

Daiichi Sankyo Company, Limited (TSE: 4568) is a global pharmaceutical company headquartered in Tokyo, Japan. Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, the firm focuses on the research, development, manufacture, and marketing of innovative pharmaceuticals, primarily in the areas of oncology, cardiovascular diseases, and vaccines. Daiichi Sankyo is also involved in the development of generic drugs and biosimilars, offering a wide range of healthcare solutions to meet the needs of patients worldwide.

Daiichi Sankyo Company (4568) Earnings & Revenues

Historic Earnings Reports

4568 Company Deck

4568 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a robust financial performance with significant revenue and profit growth, driven by strong product sales and successful patent settlements. However, slight downward adjustments in sales forecasts and potential financial uncertainties were noted.View all JP:4568 earnings summaries

4568 Stock 12 Month Forecast

Average Price Target

¥5,760.82

▲(57.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3279":"¥3,279","6356":"¥6,356","4048.25":"¥4,048.3","4817.5":"¥4,817.5","5586.75":"¥5,586.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6355.95656819776,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥6K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5760.8196971245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.76K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4667.65560477023,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.67K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3279,4048.25,4817.5,5586.75,6356],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3380,3608.9197360152125,3837.8394720304245,4066.759208045637,4295.678944060849,4524.598680076062,4753.518416091274,4982.438152106486,5211.357888121698,5440.277624136911,5669.197360152123,5898.117096167336,6127.036832182548,{"y":6355.95656819776,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3380,3563.1399767018847,3746.279953403769,3929.4199301056537,4112.559906807538,4295.699883509423,4478.8398602113075,4661.979836913192,4845.119813615077,5028.259790316961,5211.3997670188455,5394.53974372073,5577.679720422615,{"y":5760.8196971245,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3380,3479.0504311361715,3578.100862272343,3677.1512934085144,3776.201724544686,3875.2521556808574,3974.302586817029,4073.353017953201,4172.403449089372,4271.453880225544,4370.504311361715,4469.554742497887,4568.605173634058,{"y":4667.65560477023,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5870.766,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4622.649,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4773.633,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4775.594,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4266.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3379.485,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3679.618,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3612.411,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3771.535,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3280.326,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3635.143,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3523.459,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3380,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >